NEU gets a tick for recruiting extra subjects at the high dose, while still managing to complete the trial on time - - and for having only one subject withdraw.
Big tick for execution quality.
Having just one dropout is remarkably impressive, considering the impost on the participants and their carers.
This suggests a few good things:
1. side-effects don't seem to be an issue
2. at least some carers may have believed they could sense an improvement
3. we have good subject numbers to produce meaningful results.
4. NEU has demonstrated it can execute a trial well
5. the Rett carer community is really committed, which means they might fight tooth and nail to get the FDA to approve NEU's drug, should the results look good but not a slam dunk.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)